Clinical Trial Update: A Study to Evaluate Botulinum Toxin Type A for Injection（HengLi®）for Prophylactic Treatment of Chronic Migraine [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Botulinum Toxin Type A (HengLi) for prophylactic treatment of chronic migraine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Botulinum Toxin Type A (HengLi) (botulinum toxin type A)

Snippet

Sponsor: Lanzhou Institute of Biological Products Co., Ltd | Conditions: Chronic Migraine | Phase 3 | Status: UNKNOWN